Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab in advanced solid tumors after failure of first-line PD-1 inhibitor therapy
ChiCTR2200066743Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Dec 2022
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of envafolimab in Nonhematologic neoplasms, sponsored by First Hospital of China Medical University. Primary endpoints: Progression-free survival rate at 18 weeks and Overall survival time. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2200066743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066743.